Within the field of neurodegeneration, we specialize in the treatment and research of Dementia and Parkinson’s Disease. Our dedicated team focuses on these specific conditions, utilizing the latest scientific advancements and methodologies. Our commitment to excellence and innovation continues to drive our research forward, offering hope and new possibilities to those affected by these challenging conditions.
We’re committed to advancing the understanding and treatment of Dementia through pioneering clinical trials and cutting-edge research. Specializing in this complex neurodegenerative condition, we are dedicated to developing innovative therapies aimed at improving patient outcomes and quality of life. Join us in our mission to push forward the frontiers of Dementia research, striving to offer new hope and effective treatments to individuals affected by this challenging condition.
Read moreAt Julius Clinical we lead neurodegenerative disease treatments through advanced clinical trials, collaborating with experts and using cutting-edge methods to develop innovative therapies for better patient outcomes amidst nerve cell deterioration and related neurological issues.
Read moreWe’re committed to advancing the understanding and treatment of Dementia through pioneering clinical trials and cutting-edge research. Specializing in this complex neurodegenerative condition, we are dedicated to developing innovative therapies aimed at improving patient outcomes and quality of life. Join us in our mission to push forward the frontiers of Dementia research, striving to offer new hope and effective treatments to individuals affected by this challenging condition.
Read moreAt Julius Clinical we lead neurodegenerative disease treatments through advanced clinical trials, collaborating with experts and using cutting-edge methods to develop innovative therapies for better patient outcomes amidst nerve cell deterioration and related neurological issues.
Read moreOn NOVEMBER 26th, 2024, we organised the webinar: Time to event trial designs in ALS: How useful are they? During this webinar, our speakers Ruben van Eijk, Lotte Smets, Jordi van Unnik and host Lieza Exalto explored the following topics:A...
On the 27th of June, we organized the webinar: 'Clinical Consequences of the New MASLD Nomenclature' with guest speaker Prof. Maja Thiele.During this webinar, our speaker and hosts dived into the following topics:Is the MASLD nomeclature...
On October 15, at 16.00 CEST, we presented the webinar:Plasma biomarkers for diagnosis and monitoring of neurodegenerative disordersTopics that are discussed:Plasma biomarkers, such as Amyloid, pTau and NfL. Treatment effect in ne...
Explore our Neurodegeneration trial capabilities, case studies, and other resources.
"*" indicates required fields
"*" indicates required fields
